This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wyeth Misses

Wyeth (WYE) swung to a fourth-quarter profit but missed Wall Street estimates. The drug giant also set a 15-million-share stock buyback.

For the quarter ended Dec. 31, the Madison, N.J., maker of antidepressant Effexor made $732 million, or 54 cents a share, reversing the year-ago loss of $1.76 billion, or $1.32 a share. The latest quarter included a 5-cent-a-share charge for its productivity push. Excluding the charge, the latest-quarter profit was 59 cents a share, down from 64 cents a year ago and a penny shy of the Thomson First Call analyst consensus estimate. Revenue rose to $4.75 billion from $4.65 billion a year earlier but missed the $4.9 billion estimate.

The decreases in net income and diluted earnings per share before certain significant items for the 2005 fourth quarter resulted from higher research and development spending, partially offset by higher net revenue, lower cost of goods sold and selling, general and administrative expenses, both as a percentage of net revenue, lower interest expense, net and higher other income, net.

"Wyeth demonstrated strong product performance and 2005 was a year of significant strategic accomplishment," said CEO Robert Essner. "With strong growth from biotechnology products such as Enbrel and our vaccine, Prevnar, and contributions from our core pharmaceutical products such as Effexor and Protonix, Wyeth is in the strongest competitive position in its history with five product franchises exceeding one billion dollars in annual revenues."

"Wyeth's R&D continued to yield industry-leading results by filing two New Drug Applications (NDAs) in 2005 and is working toward five more for new products in the next 18 months. This was also a year in which we formed new partnership alliances, implemented a new primary care sales model in the U.S. and opened one of the world's largest integrated biotechnology manufacturing facilities. Finally, we made significant progress on diet drug litigation."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.77 -1.10%
FB $117.22 0.42%
GOOG $694.17 0.46%
TSLA $240.39 -3.00%
YHOO $36.51 -0.22%


Chart of I:DJI
DOW 17,807.54 +33.90 0.19%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs